@FiercePharma: Have you read our latest report? Not to be missed: The top 10 patent losses of 2015. Report | Follow @FiercePharma
@CarlyHFierce: ICYME: Flush-with-cash Shire revisits deal for NPS Pharma. More | Follow @CarlyHFierce
> Animal health leader Zoetis ($ZTS), under pressure to improve shareholder value since activist investor Bill Ackman bought up a $1.5 billion stake, says its first-quarter 2015 dividend will be 8.3 cents per share--15% higher than this year's dividend rate. Story
> Investors who sold shares of Allergan ($AGN) between February and April are suing Bill Ackman and Valeant ($VRX) for insider trading. More
> The FDA has cleared Teva's ($TEVA) allergy drug QNASL in children age 4 to 11. Release
> Sanofi ($SNY) has leased 40,000 square feet of office space in Miami, FL. Report
> The EU has recommended approval of Italian drugmaker Chiesi's rare eye disease drug Holoclar, the first medicine containing stem cells. Story
> Novartis ($NVS) had won approval in India to import and market its Cushing's disease drug Pasireotide without having to do local clinical trials. Story
Medical Device News
@FierceMedDev: ICYMI yesterday: FDA warns against inappropriate use of fetal ultrasound imaging and heartbeat monitoring. Article | Follow @FierceMedDev
@EmilyWFierce: Myriad Genetics stymied in BRCA breast cancer test patent battle. Story | Follow @EmilyWFierce
> Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. More
> Small cap Cerus spikes on back-to-back Intercept approvals by FDA. News
> FDA outlines UDI implementation plans for 2015. More
Biotech News
@FierceBiotech: Juno banks $265M in an IPO, pushing the next big thing in oncology. Story | Follow @FierceBiotech
@JohnCFierce: You want to start an argument? Walk into a room full of neuroscientists and shout 'amyloid beta.' | Follow @JohnCFierce
@DamianFierce: $MRK + $CBST tick-tock shows Frazier wanted $HSP decision contingency and Bonney talked him out of it. More | Follow @DamianFierce
> Gilead buys into Ono's cancer drug as it scales up in oncology. News
> Lilly makes amends with Adocia in $570M diabetes deal. Story
> Roche scuttles PhIII Alzheimer's study in yet another setback for the field. More
And Finally... According to a new investigation, hundreds of thousands of Americans are falling prey to pharma spam and buying drugs from rogue pharmacy websites. Report